Interleukin-17–targeted Treatment in patients with spondyloarthritis and associated cardiometabolic risk profile

dc.contributor.author	Queiro Silva, Rubén
dc.contributor.author	Aurrecoechea, E.
dc.contributor.author	Alonso Castro, S.
dc.contributor.author	Villa Blanco, I.
dc.contributor.author	Brandy García, A.
dc.contributor.author	Linge, R.
dc.date.accessioned	2023-11-07T09:59:00Z
dc.date.available	2023-11-07T09:59:00Z
dc.date.issued	2023
dc.identifier.citation	Frontiers in Immunology, 14, (2023); doi:10.3389/fimmu.2023.1203372
dc.identifier.issn	1664-3224
dc.identifier.uri	https://hdl.handle.net/10651/70190
dc.description.sponsorship	This study received funding for publication from Novartis. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.
dc.language.iso	eng
dc.relation.ispartof	Frontiers in Immunology
dc.rights	© Queiro, Aurrecoechea, Alonso Castro, Villa Blanco, Brandy-Garcia and Linge
dc.rights	CC Reconcimiento 4.0 Internacional
dc.rights.uri	http://creativecommons.org/licenses/by/4.0/
dc.source	Scopus
dc.source.uri	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85166403774&doi=10.3389%2ffimmu.2023.1203372&partnerID=40&md5=cf6d36eafa7ca045e31641eede96400b
dc.title	Interleukin-17–targeted Treatment in patients with spondyloarthritis and associated cardiometabolic risk profile
dc.type	journal article
dc.identifier.doi	10.3389/fimmu.2023.1203372
dc.relation.publisherversion	http://dx.doi.org/10.3389/fimmu.2023.1203372
dc.rights.accessRights	open access
dc.type.hasVersion	VoR

Este ítem está sujeto a una licencia Creative Commons